Product Images Donepezil Hydrochloride

The text is not readable.*

This text describes a chart showing the ADAS-cog change from baseline for patients taking Donepezil Hydrochloride Tablets at 5mg/day and 10mg/day, as well as those who received a placebo. The chart shows the mean (+SE) change at weeks 6, 12, 18, and 24 of drug treatment. The chart also shows clinical improvement and decline for patients taking the different treatments.*

This data represents the cumulative percentage of patients in different treatment groups (placebo, 5mg/day, and 10mg/day) based on their change in ADAS-cog score (a standardized assessment of cognitive function) after taking Donepezil Hydrochloride tablets for a certain period of time. The graph also shows the points earned for each change and no change. The higher the percentage, the more patients in that treatment group had positive changes in their cognitive function. This information can be useful for evaluating the effectiveness of Donepezil Hydrochloride tablets in treating cognitive impairment in patients.*

This is a chart representing the percentage of patients that had different levels of improvement and changes in the CIBIC-plus rating. The chart also shows the medications taken by the patients, which include Donepezil Hydrochloride Tablets 10 mg/day, Donepezil Hydrochloride Tablets 5 mg/day, and Placebo.*

This text presents a table with data regarding the change from baseline in ADAS-cog scores in patients receiving 5mg/day or 10mg/day of Donepezil Hydrochloride Tablets, as well as patients receiving a placebo. The table displays mean scores with SE values, as well as the clinical improvement observed. The weeks of drug treatment (up to 12 weeks) are also included.*

Not-Available*

This text describes a clinical study that measured the change from baseline in SIB (Severe Impairment Battery) and clinical improvement after 3 months of drug treatment with Donepezil Hydrochloride Tablets 10 mg/day compared to a placebo. No further information is available.*

This is a graph showing the change in ADCS-ADL score from the baseline for patients taking placebo and Donepezil Hydrochloride Tablets (10mg/day) over a period of 3 months. The x-axis represents months of drug treatment while the y-axis represents the mean (+SE) change from baseline. The graph indicates that patients taking Donepezil Hydrochloride Tablets showed a clinical improvement in their ADCS-ADL score, while patients taking placebo experienced a clinical decline in their score.*

The text describes a graph showing the change in ADCS-ADL (a measurement of functional abilities in individuals with Alzheimer's disease) from baseline for patients taking either Donepezil Hydrochloride tablets or a placebo at different time points (0, 5, 10, 15, and 20). The graph has a horizontal axis with values ranging from -20 to +20 and a vertical axis with the medication types. Beyond this, no further information is available.*

This appears to be a graph or chart displaying the results of a medical study or trial involving two groups taking different dosages of Donepezil Hydrochloride Tablets. The chart shows the percentages of patients who reported being "markedly improved," "moderately improved," "minimally improved," "no change," "minimally worse," "moderately worse," or "markedly worse" on the CIBIC-plus rating scale. However, without more context or a clearer image of the graph, it is difficult to provide a more detailed description.*

NDC 51407-320-30 is a package of Donepezil Hydrochloride Tablets, USP containing 23 mg of the drug per tablet, manufactured by TW1 Pharmaceuticals, Inc. with packaging by GSMS, Incorporated. The tablets should be stored at a temperature range of 20°C to 25°C and in a tight, light-resistant container as per the instructions provided by the USP. It is advised not to use the medication if the seal over the bottle opening is missing or broken. While the USP dissolution test and USP organic impurities test are pending, the medicine should be kept away from children.*